Meeting
2015 ASCO Annual Meeting
Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).
Authors
Pierre Chabot
Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada
Pierre Chabot , Jeong-Seon Ryu , Vera Gorbunova , Cristobal Belda , David Ball , Ebenezer A. Kio , Minesh Mehta , Katherine Papp , Qin Qin , Jane Qian , Kyle D. Holen , Vincent L. Giranda , John H. Suh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01657799
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2021)
DOI
10.1200/jco.2015.33.15_suppl.2021
Abstract #
2021
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.
First Author: Makoto Nishio
Poster
2021 ASCO Annual Meeting
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
First Author: Juergen Wolf
Poster
2017 ASCO Annual Meeting
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
First Author: Charles E. Geyer Jr.
Poster
2015 ASCO Annual Meeting
Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.
First Author: Suresh S. Ramalingam